产品
编 号：F041150
分子式：C19H17N5
分子量：315.37
分子式：C19H17N5
分子量：315.37
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1125758-85-1
产品详情
生物活性：
A-804598 is a CNS penetrant, competitive and selective P2X7 receptor antagonist with IC50s of 9 nM, 10 nM and 11 nM for mouse, rat and human P2X7 receptors, respectively.
体内研究：
A chroni treatment with A-804598 (intraperitoneal injection; 30 mg/kg; five times a week) decreases the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease.Animal Model:Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice
Dosage:30 mg/kg
Administration:Intraperitoneal injection; five times a week
Result:Decreased SQSTM1/p62 expression.
体外研究：
Pre-incubation with A-804598 (0.1-10 μM; 1 hour) significantly attenuates BzATP-induced cell loss in a concentration-dependent manner. 3 μM A-804598 exhibits the greatest protective effect against BzATP-induced cytotoxicity.
A-804598 is a CNS penetrant, competitive and selective P2X7 receptor antagonist with IC50s of 9 nM, 10 nM and 11 nM for mouse, rat and human P2X7 receptors, respectively.
体内研究：
A chroni treatment with A-804598 (intraperitoneal injection; 30 mg/kg; five times a week) decreases the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease.Animal Model:Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice
Dosage:30 mg/kg
Administration:Intraperitoneal injection; five times a week
Result:Decreased SQSTM1/p62 expression.
体外研究：
Pre-incubation with A-804598 (0.1-10 μM; 1 hour) significantly attenuates BzATP-induced cell loss in a concentration-dependent manner. 3 μM A-804598 exhibits the greatest protective effect against BzATP-induced cytotoxicity.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备